Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glycopeptide carboxamides active against vancomycin-resistant enterococci.

Mark J Zweifel1, Nancy J Snyder, Robin D G Cooper

  • 1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA. ZWEIFEL_MARK_J@LILLY.COM

The Journal of Antibiotics
|May 23, 2003
PubMed
Summary

New glycopeptide antibiotic amides show potent activity against resistant bacteria. These vancomycin and LY264826 derivatives are effective against staphylococci, streptococci, and vancomycin-resistant enterococci.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An inductively coupled plasma tandem mass spectrometry investigation of the activation of methane by lanthanide cations.

Physical chemistry chemical physics : PCCP·2025
Same author

The Curious Case of Pu<sup>+</sup>: Insight on 5f Orbital Activity from Inductively Coupled Plasma Tandem Mass Spectrometry (ICP-MS/MS) Reactions.

Inorganic chemistry·2024
Same author

f-Block reactions of metal cations with carbon dioxide studied by inductively coupled plasma tandem mass spectrometry.

Physical chemistry chemical physics : PCCP·2023
Same author

ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine.

Molecular cancer therapeutics·2019
Same author

Sodium Butylated Hydroxytoluene (NaBHT) as a New and Efficient Hydride Source for Pd-Catalysed Reduction Reactions.

Chemistry (Weinheim an der Bergstrasse, Germany)·2019
Same author

One-Pot Sequential Kumada-Tamao-Corriu Couplings of (Hetero)Aryl Polyhalides in the Presence of Grignard-Sensitive Functional Groups Using Pd-PEPPSI-IPent<sup>Cl</sup>.

Chemistry (Weinheim an der Bergstrasse, Germany)·2019

Area of Science:

  • Medicinal Chemistry
  • Microbiology
  • Antibiotic Development

Background:

  • Glycopeptide antibiotics like vancomycin are crucial for treating Gram-positive bacterial infections.
  • Emergence of antibiotic resistance, particularly vancomycin-resistant enterococci (VRE), necessitates the development of novel therapeutic agents.
  • Semi-synthetic modifications of existing antibiotics offer a promising strategy to overcome resistance mechanisms.

Purpose of the Study:

  • To synthesize novel glycopeptide antibiotic amides.
  • To evaluate the antimicrobial activity of these derivatives against a range of Gram-positive pathogens, including resistant strains.
  • To explore structure-activity relationships for enhanced efficacy.

Main Methods:

  • Synthesis of glycopeptide amides using PyBOP-mediated condensation.

Related Experiment Videos

  • Condensation involved vancomycin, LY264826 (A82846B), and their semi-synthetic derivatives with various amines.
  • Antimicrobial susceptibility testing against staphylococci, streptococci, and vancomycin-resistant enterococci.

    • Main Results:

    • Amides of LY264826 and vancomycin exhibited excellent activity against staphylococci and streptococci compared to parent compounds.
    • N-alkylated derivatives of LY264826 and vancomycin demonstrated significant activity against vancomycin-resistant enterococci.
    • These novel amides were also effective against other Gram-positive pathogens like Staphylococcus aureus, S. haemolyticus, S. epidermidis, and Streptococcus pneumoniae.

    Conclusions:

    • PyBOP-mediated synthesis yields potent glycopeptide antibiotic amides.
    • N-alkylation of vancomycin and LY264826 derivatives enhances activity against challenging Gram-positive pathogens, including VRE.
    • These findings support the development of novel glycopeptide amides as potential treatments for resistant bacterial infections.